Zinger Key Points
- Hoth revealed the expansion of its FDA-cleared first-in-human clinical trial for cancer patients of HT-001 at the University of Miami.
- Hoth said it will update investors and patients on this ongoing trial in the first quarter of 2024.
- Discover Fast-Growing Stocks Every Month
Hoth Therapeutics, Inc. HOTH shares are trading higher after the company announced the expansion of its FDA-cleared first-in-human clinical trial for cancer patients of HT-001 at the University of Miami.
This First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose-ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.
"Coupled with approval at Washington University of St. Louis and MD Anderson Cancer Center, University of Miami will be our third site approved to host our trial and bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments," said Hoth Therapeutics Chief Executive Officer, Robb Knie.
The company said it will update investors and patients on this ongoing trial in the first quarter of 2024.
Read Next: Why Are Bitcoin Company Bit Digital Shares Shooting Higher Wednesday?
Price Action: HOTH shares are trading higher by 8.82% to $1.48 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
